A study of the HLA-DR region in clinical subgroups of multiple-sclerosis and its influence on prognosis

Journal of the Neurological Sciences

Volumn 165, Issue 1, 1999, Pages 77-83

  McDonnell, G V ^a   Mawhinney, H ^b   Graham, C A ^b   Hawkins, S A ^a,c   Middleton, D ^b,c,d  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Genes; HLA; HLA DR2; Major histocompatibility complex; Multiple sclerosis; Primary progressive; Prognosis

Indexed keywords

HLA DR ANTIGEN; HLA DR2 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC MARKER; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ALLELES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS; NORTHERN IRELAND; PHENOTYPE; PROGNOSIS; RECURRENCE;

EID: 0033136817     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00084-2     Document Type: Article

References (43)

1. Gowers W.R. 2nd Ed A manual of diseases of the nervous system. 2:1893;Churchill, London.
2. Pratt R.T.C., Compston N.D., McAlpine D. The familial incidence of multiple sclerosis and it's significance. Brain. 74:1951;191-232.
3. Sadovnick A.D., Baird P.A., Ward R.H. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 29:1988;533-541.
4. Mumford C.J., Wood N.W., Kellar-Wood H., Thorpe J.W., Miller D.H., Compston D.A.S. The British Isles survey of multiple sclerosis in twins. Neurology. 44:1994;11-15.
5. Sadovnick A.D., Armstrong H., Rice G.P.A., Bulman D., Hashimoto L., Paty D.W., Hashimoto S.A., Warren S., Hader W., Murray T.J., Seland T.P., Metz L., Bell R., Duquette P., Gray T., Nelson R., Weinshenker B., Brunet D., Ebers G.C. A population-based study of multiple sclerosis in twins: update. Ann Neurol. 33:1993;281-285.
6. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet. 1:1972;1240-1241.
7. Compston D.A.S., Batchelor J.R., McDonald W.I. B lymphocyte alloantigens associated with multiple sclerosis. Lancet. 2:1976;1261-1265.
8. Terasaki P.I., Park M.S., Opelz G., Ting A. Multiple sclerosis and high incidence of a B lymphocyte antigen. Science. 193:1976;1245-1247.
9. Swingler R.J., Kirk P.F., Darke C., Compston D.A.S. HLA and multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry. 50:1987;1153-1155.
10. Cullen C.G., Middleton D., Savage D.A., Hawkins S.A. HLA-DR and -DQ DNA genotyping in multiple sclerosis patients in Northern Ireland. Hum Immunol. 30:1991;1-6.
11. Francis D.A., Batchelor J.R., McDonald W.I., Hing S.N., Dodi I.A., Fielder A.H.L., Hern J.E.C., Downie A.W. Multiple sclerosis in north-east Scotland. An association with HLA-DQw1. Brain. 110:1987;181-196.
12. Tienari P.J., Wikstrom J., Koskimies S., Partanen J., Palo J., Peltonen L. Reappraisal of HLA in multiple sclerosis: close linkage in multiplex families. Eur J Hum Genet. 1:1993;257-268.
13. Hillert J., Käll T., Vrethem M., Fredrikson S., Ohlson M., Olerup O. The HLA-Dw2 haplotype segregates closely with multiple sclerosis in multiplex families. J Neuroimmunol. 50:1994;95-100.
14. Voskuhl R.R., Goldstein A.M., Simonis T., Davey R.J., McFarland H.F. DR2/DQw1 inheritance and haplotype sharing in affected siblings from multiple sclerosis families. Ann Neurol. 39:1996;804-807.
15. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet. 13:1996;469-471.
16. McAlpine D., Compston N. Some aspects of the natural history of disseminated sclerosis. QJM. 82:1952;135-167.
17. Weinshenker B.G. Natural history of multiple sclerosis. Ann Neurol. 36:1994;S6-S11.
18. Minderhoud J.M., van der Hoeven J.H., Prange A.J.A. Course and prognosis of chronic progressive multiple sclerosis. Acta Neurol Scand. 78:1988;10-15.
19. Van Lambalgen R.V., Sanders E.A.C.M., D'Amaro J. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis: a role for sex hormones and microbial infections in the development of autoimmunity. J Neurol Sci. 76:1986;13-21.
20. Larsen J.P., Kvaale G., Riise T., Nyland H., Aarli J.A. Multiple sclerosis - more than one disease? Acta Neurol Scand. 72:1985;145-150.
21. Thompson A.J., Kermode A.G., Wicks D., MacManus D.G., Kendall B.E., Kingsley D.P.E., McDonald W.I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 29:1991;53-62.
22. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
23. Kidd D., Barker G.J., Tofts P.S., Gass A., Thompson A.J., McDonald W.I., Miller D.H. The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis. J Neurol. 244:1997;125-130.
24. Census Office for Northern Ireland, 1991. Census Summary Report, Table 7.
25. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
26. McDonnell G.V., Hawkins S.A. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology. 50:1998;423-428.
27. Filippi M., Campi A., Martinelli V., Rodegher M., Scotti G., Canal N., Comi G. A brain MRI study of different types of chronic-progressive multiple sclerosis. Acta Neurol Scand. 91:1995;231-233.
28. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
29. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
30. Bland J.M., Altman D.G. Multiple significance tests: the Bonferroni method. BMJ. 310:1995;170.
31. Madigand M., Oger J.J.-F., Fauchet R., Sabouraud O., Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci. 53:1982;519-529.
32. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Möller E., Carlsson B., Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA. 86:1989;7113-7117.
33. Hillert J., Gronning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 55:1992;887-890.
34. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., Rodriguez M. Major histocompatibiltiy complex class II alleles and the course and outcome of MS: a population-based study. Neurology. 51:1998;742-747.
35. Paty D.W., Dossetor J.B., Stiller C.R., Cousin H.K., Marchuk L., Furesz J., Boucher D.W. HLA in multiple sclerosis. J Neurol Sci. 32:1977;371-379.
36. Reekers P., Hommes O.R., Creemers-Molenaar J., Wijnings J., Kunst V.A.J.M., Van Rood J.J. HLA-typing and lymphocyte population studies in patients with multiple sclerosis. J Neurol Sci. 33:1977;143-153.
37. Poser S., Ritter G., Grosse-Wilde H., Kuwert E.K., Raun N.E. HLA-antigens and the prognosis of multiple sclerosis. J Neurol. 225:1981;219-221.
38. Dejaegher L., de Bruyere M., Ketelaer P., Carton H. HLA antigens and progression of multiple sclerosis. Part II. J Neurol. 229:1983;167-174.
39. Runmarker B., Martinsson T., Wahlstrom J., Andersen O. HLA and prognosis in multiple sclerosis. J Neurol. 241:1994;385-390.
40. Jersild C., Fog T., Hansen G.S., Thomsen M., Svejgaard A., Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet. 2:1973;1221-1224.
41. Stendahl-Brodin L., Link H., Moller E., Norrby E. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF. Acta Neurol Scand. 59:1979;297-308.
42. Engell T., Raun N.E., Thomsen M., Platz P. HLA and heterogeneity of multiple sclerosis. Neurology. 32:1982;1043-1046.
43. Duquette P., Decary F., Pleines J., Boivin D., Lamoureux G., Cosgrove J.B.R., Lapierre Y. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci. 12:1985;106-110.